11 Oversold NASDAQ Stocks to Buy Right Now

Page 9 of 10

2. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Perf YTD: -49.41%

Analyst Upside: 165.00%

Number of Hedge Fund Holders: 50

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a commercial-stage biopharmaceutical company that discovers and develops RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities to treat rare diseases. The company has several approved products to treat Duchenne muscular dystrophy and is developing potential therapeutical candidates for more disorders, including neuromuscular and central nervous system-related disorders. Its pipeline comprises more than 40 programs at various discovery, pre-clinical, and clinical development stages.

On April 16, Yanan Zhu, an analyst from Wells Fargo, maintained a Buy rating on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) with an associated price target of $115.00. The analyst supported the Buy rating with several factors, including the company’s progress in its LGMD clinical programs. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is on track with its SRP-9003 program for LGMD2E/R4 and expects to report Phase 3 EMERGENE study data by mid-2025.

The analyst also highlighted the promising regulatory progress for SRP-9003, with a pre-BLA meeting confirming accelerated approval pathway eligibility. Sarepta Therapeutics, Inc.’s (NASDAQ:SRPT) plan to file a BLA in H2 2025 is hailed as a positive catalyst by the analyst, supporting the Buy rating. In addition, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has had reassuring interactions with the FDA about its SRP-9005 program, pointing towards a clear future path for its clinical trials.

Page 9 of 10